Hook & thesis
I am buying Rocket Lab (RKLB) today because it is the best public expression of the growth and defense-driven demand in space right now. Unlike SpaceX, which — despite its recent public splash — is overwhelmingly large, vertically integrated and now substantially priced for perfection, Rocket Lab gives public-market investors a tradable, high-leverage bet on launch cadence, the commercial small-sat market and growing defense revenue. RKLB combines a chunky backlog, a string of recent contract wins and a major product milestone on the horizon: Neutron's first flight.
Yes, valuation is rich - the company trades at about 60x trailing sales and a market cap in the neighborhood of $40.8 billion - but the public optionality and a steady cadence of defense and launch milestones create near-term rerating opportunities that are easier to capture in a listed stock than by trying to buy SpaceX exposure. My trade is tactical: enter at the current market price, cap downside with a firm stop, and hold through the next major operational catalysts.
What Rocket Lab does and why the market should care
Rocket Lab operates two core segments: Launch Services and Space Systems. The Launch Services business sells dedicated and rideshare launches. Space Systems builds satellites, components and offers on-orbit mission services. The combination matters: Rocket Lab is not just selling rockets, it is increasingly selling vertically integrated mission solutions to commercial customers and defense primes. That evolution helps convert launch strength into recurring, higher-margin systems work and longer-term contracts.
Why this matters now: the company reported record quarterly revenue and a growing backlog (reported backlog figure cited in public coverage is $2.36 billion), and has just won a major defense award - a $397 million U.S. Space Force contract to develop, launch, and operate stackable 'Flatellites'. That single contract rivals more than six months of current annual revenue and is a concrete example of Rocket Lab transforming into a vertically integrated defense contractor.
Numbers that support the buy case
- Current price: $68.37; previous close: $72.57.
- Market cap: roughly $40.84 billion.
- Valuation on sales: roughly 60x price-to-sales and an enterprise value around $44.30 billion (EV/sales ~57.6x).
- Profitability: still unprofitable on GAAP metrics (negative EPS of about -$0.26 in the last reporting window) and negative free cash flow of roughly -$371 million.
- Backlog and contracts: a reported backlog of roughly $2.36 billion and a $397 million Space Force contract awarded 08/18/2026.
- Share price action: 52-week range is $37.57 - $150.9999 demonstrating both large upside and downside realized over the last year.
Valuation framing
It is fair to call Rocket Lab expensive on a simple sales multiple. At roughly 60x trailing revenue the stock requires the market to price in a sizeable expansion of revenue and meaningful margin improvement over the next several years. That is a tall order. But the valuation premium is, in part, compensation for future optionality: Neutron (a medium-lift vehicle that, if successful, opens larger commercial and national security addressable markets), integrated mission contracts (which lift lifetime customer value) and a sizable backlog that should convert into near-term revenue.
Compare this to SpaceX: SpaceX is larger, more vertically integrated and will capture share in launch and broadband via Starlink, but it is also less accessible to retail investors and carries its own concentration risks. Rocket Lab gives public investors a cleaner, more liquid way to run leveraged beta on commercial launch growth plus near-term defense revenue expansion.
Technical and market-structure considerations
- Momentum: the stock has pulled back to an RSI near 38.8, with short-term moving averages below medium-term averages, indicating recent selling pressure.
- Short interest: recent data shows short interest near 45.8 million shares, and daily short-volume readings indicate persistent short activity. That increases volatility but also increases the potential impact of positive operational beats on price.
Trade plan (actionable)
Horizon: long term (180 trading days). I expect to hold through key operational milestones, including the initial Neutron flight window and conversion of a portion of the backlog into revenue.
| Entry | Stop | Target | Trade Direction | Time Horizon |
|---|---|---|---|---|
| $68.37 | $55.00 | $111.00 | Long | Long term (180 trading days) |
Rationale: entry at $68.37 captures recent weakness and improves upside/reward dynamics. Stop at $55.00 limits downside to key technical support zone and keeps risk manageable relative to volatility. The target of $111.00 reflects a realistic re-rating toward the analyst-consolidated targets published in the market and implies significant upside from current levels if Rocket Lab executes on Neutron and converts backlog into revenue.
Catalysts (what will move the stock)
- Neutron first flight and demonstration of reusability or performance - a successful initial launch is the single biggest valuation trigger.
- Execution on the $397 million Space Force program and further task orders from defense customers that expand recurring mission revenue.
- Quarterly revenue beats and margin improvement as backlog converts; management commentary that shows improving unit economics for launches and space systems work.
- Additional commercial manifest bookings or larger integrated-mission awards that demonstrate a pivot from pure launch-seller to program integrator.
Risks and counterarguments
Investing in RKLB is not without material hazards. Below are the principal risks I weigh into position sizing and the stop placement.
- Execution risk on Neutron - Neutron has not yet flown. Slippages or a failed first flight would likely crater sentiment and could remove the primary re-rating catalyst, sending the stock far below current levels.
- Valuation steepness - At roughly 60x sales, the stock is priced for dramatic future growth and margin expansion. Disappointing revenue growth or persistent losses would pressure multiples severely.
- Cash burn and negative free cash flow - The company reported roughly -$371 million in free cash flow in the last period. Sustained negative cash flow may force dilution or increased leverage if revenue growth disappoints.
- Competitive pressure - While Rocket Lab is nimbler in the small-sat market, larger players (including SpaceX) have scale advantages and could undercut pricing or capture customers with integrated offerings (Starlink + rideshare or Falcon-class services).
- Market sentiment / macro - Space equities have historically been volatile and sensitive to both macro sell-offs and headline-driven flows (e.g., SpaceX-related news or defense procurement cycles).
Counterargument: Critics argue that you should own SpaceX instead because it controls the most profitable, high-volume assets (Starlink and Falcon/Starship family) and has a bigger, less risky long-term monetization pathway. That is a fair point: SpaceX will likely capture far more aggregate revenue over time. But for public-market traders and smaller accounts, SpaceX exposure is either inaccessible, overpriced relative to public peers or concentrated in a single, gigantic name. Rocket Lab offers a tradable, public-sized option with explicit near-term catalysts and sizeable defense incumbency - attributes that, to me, justify preferring RKLB given the trade structure and timeline I propose.
What would change my mind
I would reduce or exit this position if any of the following occur: an official announcement that Neutron's first flight is delayed beyond 2027, consistent quarterly misses in revenue conversion from backlog, evidence of accelerating cash burn without clear financing plans, or the emergence of a defense contract performance issue that materially impairs the reported $397M award. Conversely, successful Neutron demonstration and steady backlog conversion would likely lead me to add to the position.
Conclusion
Rocket Lab is a high-conviction trade for me right now because it provides public-market investors with leverage to the commercialization of launch and a growing defense-services footprint — without the access and concentration issues that come with SpaceX. The valuation is demanding, and that requires disciplined risk management: a precise entry at $68.37, a strict stop at $55.00 and a patient hold through the next major operational milestones, especially Neutron's debut. If execution follows the narrative, the stock can re-rate meaningfully; if execution fails, the stop preserves capital and lets me reassess on fresh fundamentals.
Trade idea snapshot: Buy RKLB at $68.37, stop $55.00, target $111.00, hold through long term (180 trading days) while monitoring Neutron progress and contract execution.